270 related articles for article (PubMed ID: 31581148)
1. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.
Lam AN; Aksit MA; Vecchio-Pagan B; Shelton CA; Osorio DL; Anzmann AF; Goff LA; Whitcomb DC; Blackman SM; Cutting GR
J Clin Invest; 2020 Jan; 130(1):272-286. PubMed ID: 31581148
[TBL] [Abstract][Full Text] [Related]
2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
Sato Y; Thomas DY; Hanrahan JW
J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
[TBL] [Abstract][Full Text] [Related]
3. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
[TBL] [Abstract][Full Text] [Related]
4. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
[TBL] [Abstract][Full Text] [Related]
5. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice.
Liu X; Li T; Riederer B; Lenzen H; Ludolph L; Yeruva S; Tuo B; Soleimani M; Seidler U
Pflugers Arch; 2015 Jun; 467(6):1261-75. PubMed ID: 24965066
[TBL] [Abstract][Full Text] [Related]
6. SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.
Gorrieri G; Zara F; Scudieri P
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204703
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
[TBL] [Abstract][Full Text] [Related]
8. Genetic modifiers of cystic fibrosis-related diabetes.
Blackman SM; Commander CW; Watson C; Arcara KM; Strug LJ; Stonebraker JR; Wright FA; Rommens JM; Sun L; Pace RG; Norris SA; Durie PR; Drumm ML; Knowles MR; Cutting GR
Diabetes; 2013 Oct; 62(10):3627-35. PubMed ID: 23670970
[TBL] [Abstract][Full Text] [Related]
9. Identification of single nucleotide variants in SLC26A9 gene in patients with cystic fibrosis (p.Phe508del homozygous) and its association to Orkambi® (Lumacaftor and Ivacaftor) response in vitro.
Santos LG; Pereira SV; Kmit AHP; Bonadia LC; Bertuzzo CS; Ribeiro JD; Mazzola TN; Marson FAL
Gene; 2023 Jun; 871():147428. PubMed ID: 37068695
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis.
Aksit MA; Ling H; Pace RG; Raraigh KS; Onchiri F; Faino AV; Pagel K; Pugh E; Stilp AM; Sun Q; Blue EE; Wright FA; Zhou YH; Bamshad MJ; Gibson RL; Knowles MR; Cutting GR; Blackman SM;
Am J Hum Genet; 2022 Oct; 109(10):1894-1908. PubMed ID: 36206743
[TBL] [Abstract][Full Text] [Related]
11. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
[TBL] [Abstract][Full Text] [Related]
12. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.
Chang MH; Plata C; Sindic A; Ranatunga WK; Chen AP; Zandi-Nejad K; Chan KW; Thompson J; Mount DB; Romero MF
J Biol Chem; 2009 Oct; 284(41):28306-28318. PubMed ID: 19643730
[TBL] [Abstract][Full Text] [Related]
13. Hydrokinetic pancreatic function and insulin secretion are moduled by Cl
Li T; di Stefano G; Raza GS; Sommerer I; Riederer B; Römermann D; Tan X; Tan Q; Pallagi P; Hollenbach M; Herzig KH; Seidler U
Acta Physiol (Oxf); 2022 Jan; 234(1):e13729. PubMed ID: 34525257
[TBL] [Abstract][Full Text] [Related]
14. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study.
Soave D; Miller MR; Keenan K; Li W; Gong J; Ip W; Accurso F; Sun L; Rommens JM; Sontag M; Durie PR; Strug LJ
Diabetes; 2014 Jun; 63(6):2114-9. PubMed ID: 24550193
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.
Li W; Soave D; Miller MR; Keenan K; Lin F; Gong J; Chiang T; Stephenson AL; Durie P; Rommens J; Sun L; Strug LJ
Hum Genet; 2014 Feb; 133(2):151-61. PubMed ID: 24057835
[TBL] [Abstract][Full Text] [Related]
16. Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits.
Aksit MA; Pace RG; Vecchio-Pagán B; Ling H; Rommens JM; Boelle PY; Guillot L; Raraigh KS; Pugh E; Zhang P; Strug LJ; Drumm ML; Knowles MR; Cutting GR; Corvol H; Blackman SM
J Clin Endocrinol Metab; 2020 May; 105(5):1401-15. PubMed ID: 31697830
[TBL] [Abstract][Full Text] [Related]
17. Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevance.
El Khouri E; Touré A
Int J Biochem Cell Biol; 2014 Jul; 52():58-67. PubMed ID: 24530837
[TBL] [Abstract][Full Text] [Related]
18. Characterization of SLC26A9 in patients with CF-like lung disease.
Bakouh N; Bienvenu T; Thomas A; Ehrenfeld J; Liote H; Roussel D; Duquesnoy P; Farman N; Viel M; Cherif-Zahar B; Amselem S; Taam RA; Edelman A; Planelles G; Sermet-Gaudelus I
Hum Mutat; 2013 Oct; 34(10):1404-14. PubMed ID: 24272871
[TBL] [Abstract][Full Text] [Related]
19. Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis.
Miller MR; Soave D; Li W; Gong J; Pace RG; Boëlle PY; Cutting GR; Drumm ML; Knowles MR; Sun L; Rommens JM; Accurso F; Durie PR; Corvol H; Levy H; Sontag MK; Strug LJ
J Pediatr; 2015 May; 166(5):1152-1157.e6. PubMed ID: 25771386
[TBL] [Abstract][Full Text] [Related]
20. The Potential Causes of Cystic Fibrosis-Related Diabetes.
Coderre L; Debieche L; Plourde J; Rabasa-Lhoret R; Lesage S
Front Endocrinol (Lausanne); 2021; 12():702823. PubMed ID: 34394004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
